InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer
Results presented on a predictive signature capable of identifying non-small cell lung cancer patients that will benefit most from immune checkpoint inhibitors.